DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Market Closed - Börse Stuttgart 12:08:25 2024-05-17 EDT | ||
| 0.45 EUR | -2.17% |
|
| Current month | -10.00% | ||
| 1 month | -15.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.45 | -2.17% |
| 24-05-16 | 0.46 | +21.05% |
| 24-05-15 | 0.38 | 0.00% |
| 24-05-14 | 0.38 | +2.70% |
| 24-05-13 | 0.37 | +5.71% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 12:08 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D88 |
| ISIN | DE000MG0D888 |
| Date issued | 2024-03-18 |
| Strike | 425 $ |
| Maturity | 2024-12-20 (215 Days) |
| Parity | 10 : 1 |
| Emission price | 0.52 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.88 € |
|---|---|
| Lowest since issue | 0.34 € |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
220.1
USD
Average target price
363.9
USD
Spread / Average Target
+65.34%
- Stock Market
- Certificates
- Certificat
